{"id":"placebo-to-palonosetron","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"2-5%","effect":"Vomiting"},{"rate":"2-5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Palonosetron is a selective serotonin 5-HT3 receptor antagonist that has a longer half-life compared to other 5-HT3 antagonists, allowing for once-daily dosing. This mechanism of action helps to prevent the activation of the 5-HT3 receptors in the central nervous system, which are responsible for nausea and vomiting.","oneSentence":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:57.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy"},{"name":"Prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":"Breast Carcinoma","enrollment":1363},{"nctId":"NCT06540885","phase":"PHASE4","title":"A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery","status":"RECRUITING","sponsor":"University of Malaya","startDate":"2025-01-06","conditions":"Postoperative Nausea and Vomiting, Scoliosis","enrollment":74},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT01836705","phase":"PHASE1","title":"Effect of SAR302503 on ECG Activity in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-05","conditions":"Neoplasm Malignant","enrollment":60},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":"Post COVID-19 Condition, Long COVID Syndrome, Persistent COVID-19","enrollment":90},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT00553059","phase":"PHASE3","title":"Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":62},{"nctId":"NCT00903396","phase":"PHASE2","title":"Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer","enrollment":7},{"nctId":"NCT00661674","phase":"NA","title":"Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-04","conditions":"Substance-Related Disorders","enrollment":10},{"nctId":"NCT02650479","phase":"PHASE1","title":"Study of the Effects of Intravenous Exenatide on Cardiac Repolarization","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2016-01","conditions":"Healthy Adult Male and Female Volunteers","enrollment":82},{"nctId":"NCT02203253","phase":"PHASE3","title":"Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2014-07","conditions":"Neoplasms","enrollment":642},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT00952133","phase":"PHASE4","title":"Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-07","conditions":"PONV","enrollment":118},{"nctId":"NCT01442376","phase":"PHASE3","title":"Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-09","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":502},{"nctId":"NCT01395901","phase":"PHASE3","title":"Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-06","conditions":"Postoperative Nausea and Vomiting","enrollment":670},{"nctId":"NCT01568268","phase":"PHASE3","title":"Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Laparoscopic Gynecologic, Abdominal, Other Surgery, General Anesthesia","enrollment":384},{"nctId":"NCT00415103","phase":"PHASE4","title":"AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-11","conditions":"Leukemia, Lymphoma","enrollment":196}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Palonosetron","genericName":"Placebo to Palonosetron","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy. Used for Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy, Prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}